Navigation Links
Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
Date:4/26/2010

RYE, N.Y., April 26 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that the company is now enrolling Phase III clinical trials for CM-AT, its autism treatment, at the UC Davis MIND Institute (Medical Investigation of Neurodevelopmental Disorders).

UC Davis MIND Institute joins Curemark's network of more than 12 sites across the country conducting CM-AT trials with a total 170 children.  The MIND Institute is an internationally renowned research center for understanding autism and other neurodevelopmental disorders.  With a staff of over 250, the center brings together experts in neuroscience, education, immunology, genetics, molecular biology, psychology and developmental pediatrics.

"We are very pleased to be working with the MIND Institute, one of the premier research institutions in the world for autism and other neurological disorders," said Dr. Joan Fallon, Curemark founder and CEO.  "The MIND Institute is renowned as a leader for its state-of-the-art research and interdisciplinary approach to finding innovative new ways to treat neurodevelopmental conditions."    

Curemark's CM-AT is based on Dr. Fallon's research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein.  The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function.  CM-AT, which recently was designated by the FDA as a Fast Track drug, will be one of the first therapies to address the underlying physiology of autism, rather than just treat its symptoms.  

For information on participating in the Curemark CM-AT autism trials, log on to www.clinicaltrials.gov and search "Curemark."

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Appoints Preeminent Pediatrics Gastroenterologist
2. Curemark Closes Series A Financing
3. Curemark CEO Presents at Epigenomics Conference
4. Curemark Announces Senior Executive Promotions
5. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
6. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
7. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
8. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
9. DAVISCO Foods International, Inc. and MEGGLE Group Announce a Joint Venture for the Production of Pharmaceutical Lactose.
10. TOPICA Names Mark W. Davis Vice President of Clinical Development
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017  OrthoAccel ® Technologies, ... (JCO) has published "The Effect of Vibration on ... Conducted by Dr. S. Jay Bowman , this ... II malocclusions, AcceleDent,s SoftPulse Technology ® speeds up ... also reducing the number of days to move the ...
(Date:1/17/2017)... , Jan 17, 2017 Research and Markets ... Healthcare Industry 2016-2020" report to their offering. ... The global fluoropolymer market in ... the period 2016-2020. Global Fluoropolymer Market in the ... analysis with inputs from industry experts. The report covers the market ...
(Date:1/17/2017)... 2017 Following an initial analysis, the ... Food and Drug Administration,s (FDA,s) final regulatory guidance ... by Pharmacies and Outsourcing Facilities." In its final ... pre-packaging -- which would have put patients at ... term care (LTC) pharmacies.  The ...
Breaking Medicine Technology:
(Date:1/17/2017)... MD (PRWEB) , ... January 17, 2017 , ... SC&H ... the firm as a Principal in its IT Advisory Services practice . Rossi ... recent months as market demand for strategic IT guidance grows, and the practice continues ...
(Date:1/17/2017)... ... January 17, 2017 , ... Seceon , the ... in real-time, today announced a strategic partnership with TechLab Security, a ... Seceon partners, TechLab Security has become a strategic partner and a value added ...
(Date:1/17/2017)... ... January 17, 2017 , ... The Sharie Withers Agency, a ... the latest beneficiary of their thriving community involvement program. The current campaign fundraises ... the dreams of terminally ill patients. Donations to this worthy cause may now ...
(Date:1/17/2017)... ... ... people make New Year’s resolutions or renew their commitment to better health with the start ... who want to kick off 2017 with better smiles. Dr. Mondavi is offering several promotions ... include: , , A new patient package for just $49, which ...
(Date:1/17/2017)... ... January 17, 2017 , ... Twelve ... State University’s Athletic Training Education program forged a relationship built upon the foundation ... Program, which is consists of both student members and certified members of the ...
Breaking Medicine News(10 mins):